

Clinical trial: evaluation of gastric acid suppression with three doses of immediate-release esomeprazole in the fixed-dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric-coated esomeprazole 20 mg: a randomized, open-label, Phase I study in healthy volunteers

P. Miner Jr*, J. Plachetka†, E. Orlemans‡, J. G. Fort† & M. Sostek‡

*Oklahoma Foundation for Digestive Research, Oklahoma City, OK, USA.

†POZEN Inc., Chapel Hill, NC, USA.

‡AstraZeneca US, Wilmington, DE, USA.

Correspondence to:

Dr P. Miner Jr, Oklahoma Foundation for Digestive Research, 1000 North Lincoln Boulevard, Suite 210, Oklahoma City, OK 73104, USA.
E-mail: philip-miner@ouhsc.edu

Publication data

Submitted 1 April 2010
First decision 13 April 2010
Resubmitted 13 May 2010
Accepted 16 May 2010
Epub Accepted Article 18 May 2010

SUMMARY

Background

PN 400 is a fixed-dose combination formulated to provide sequential delivery of immediate-release (IR) esomeprazole and enteric-coated (EC) naproxen.

Aim

To evaluate gastric acid suppression with three doses of esomeprazole in PN 400 compared with EC esomeprazole 20 mg.

Methods

In this Phase I, randomized, open-label study, 28 healthy adults received PN 400 b.d. (naproxen 500 mg plus esomeprazole 10, 20 and 30 mg) and non-EC naproxen 500 mg b.d. plus EC esomeprazole 20 mg o.d., each for 9 days in a crossover fashion. The primary endpoint was percentage of time on day 9 that intragastric pH was >4.0; secondary endpoints included pharmacokinetics and safety.

Results

Day 9 percentage of time where intragastric pH was >4.0 was 76.5%, 71.4%, 40.9% and 59.9% for PN 400 containing 30, 20 and 10 mg esomeprazole, and naproxen plus esomeprazole 20 mg respectively. This was significantly greater for PN 400 containing 30 and 20 mg esomeprazole vs. naproxen plus esomeprazole 20 mg (95% CI: 13.0–26.0 and 7.8–20.7 respectively). The pharmacokinetics of PN 400 were consistent with its formulation. No serious adverse events occurred.

Conclusion

PN 400 containing 20 mg esomeprazole was the lowest dose to achieve gastric acid suppression comparable to EC esomeprazole 20 mg and was selected for further evaluation.

Aliment Pharmacol Ther 2010; **32**: 414–424

INTRODUCTION

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most commonly used drugs worldwide, used by more than 30 million people every day.¹ However, they are associated with a substantial risk of upper gastrointestinal adverse events, ranging from ulcers to serious ulcer complications such as perforation, obstruction and bleeding.²

Treatment guidelines generally recommend that patients requiring chronic NSAID therapy who have risk factors for gastrointestinal ulcer complications (e.g. advanced age, a history of gastroduodenal ulcers or concomitant use of corticosteroids, aspirin and/or anti-coagulants^{3, 4}) should be treated with cyclo-oxygenase-2 selective NSAIDs or traditional, nonselective NSAIDs plus gastroprotective co-therapy. In particular, enteric-coated (EC) proton pump inhibitors have well-documented efficacy for reducing the incidence of NSAID-associated endoscopic ulcers and upper gastrointestinal symptoms,^{5, 6} and are recognized as an effective gastroprotective strategy for at-risk patients.⁴

However, despite clinical guidelines, evidence from practice suggests that gastroprotective co-therapy strategies are underutilized by physicians⁷ and poorly adhered to by patients.^{8–11} Partly as a result of this, there has been growing interest in the use of fixed-dose combination therapies of NSAIDs with gastroprotective agents in a single tablet to, among other potential benefits, improve patient adherence.

PN 400 (VIMOVO; AstraZeneca, Wilmington, DE, USA and POZEN, Inc., Chapel Hill, NC, USA) is a fixed-dose combination of EC naproxen 500 mg and immediate-release (IR) esomeprazole 20 mg that is in development for the treatment of the signs and symptoms of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis in patients at risk for developing NSAID-associated gastric ulcers. Naproxen is a nonselective NSAID with a well-established efficacy and safety profile^{12–14} and esomeprazole is a proton pump inhibitor with effective gastric acid suppression¹⁵ that, when administered as an EC preparation, has demonstrated clinical efficacy to reduce the occurrence of endoscopic gastric and duodenal ulcers in at-risk patients using NSAIDs.¹⁶ The PN 400 single-tablet formulation comprising an EC naproxen core surrounded by an IR esomeprazole mantle has been designed to provide sequential delivery of gastroprotective esomeprazole before systemic exposure to naproxen.

In this study, the pharmacokinetics, pharmacodynamics and safety of three different dose formulations of

PN 400 were evaluated and compared with naproxen 500 mg and EC esomeprazole 20 mg, with the aim of determining levels and time to exposure for these drugs, and determining the dose of IR esomeprazole in PN 400 to provide gastric acid suppression similar to EC esomeprazole.

MATERIALS AND METHODS

Study design

This was a prospective, randomized, Phase I, open-label, single-centre, cross-over study comprising four treatment periods that was conducted in the US between 3 April and 25 June 2007.

On day 1 of the first treatment period, study participants were randomized into one of four treatment sequences to receive each of four treatments for 9 days in a crossover fashion. There was a washout period of ≥ 12 days between treatments (Table 1). Study medication was administered orally with 240 mL of water 60 min before standardized meals in the morning and evening. All study medication was administered at the study site by staff, with a mouth check performed to ensure treatment compliance.

Participants were randomized into treatment sequences according to their unique treatment number, which was assigned consecutively from a randomization schedule provided by POZEN following completion of screening.

The study was reviewed and approved by an Investigational Review Board at the study site and all participants gave written, informed consent in accordance with the 1996 Declaration of Helsinki.

Table 1 | Study treatment

Treatment	Study medication
PN 400/E30	EC naproxen 500 mg/IR esomeprazole 30 mg b.d.
PN 400/E20	EC naproxen 500 mg/IR esomeprazole 20 mg b.d.
PN 400/E10	EC naproxen 500 mg/IR esomeprazole 10 mg b.d.
Naproxen + EC E20	Non-EC naproxen* 500 mg b.d. and EC esomeprazole 20 mg o.d.

b.d., twice daily; EC, enteric coated; IR, immediate release; o.d., once daily.

*Non-EC naproxen was inadvertently used as a control instead of EC naproxen.

Participants

Eligible participants were healthy adults aged 18–55 years who tested negative for *Helicobacter pylori* infection and had no history of peptic ulcer disease or other acid-related gastrointestinal symptoms. Participants with a history of hypersensitivity, allergy or intolerance to any NSAID or proton pump inhibitor were excluded from the study. Other exclusion criteria included the presence of any uncontrolled acute or chronic illness, any gastrointestinal disorder causing impaired drug absorption and a history of alcohol or drug abuse.

The ingestion of grapefruit juice was disallowed within 10 days of first dose and throughout the study. The use of any concomitant medications was not permitted unless approved by the principal investigator. Specifically, the use of any proton pump inhibitor or gastroprotective agent, any misoprostol-containing product, sucralfate, antibiotics, antacid or Pepto-Bismol (Procter & Gamble, Cincinnati, OH, USA) was disallowed within 14 days prior to dosing and throughout the study. Additionally, within 7 days prior to dosing and throughout the study, the use of any NSAID, bisphosphonate, steroid, anticoagulant, anticholinergic or monoamine oxidase inhibitor was also disallowed.

During a screening period of up to 14 days, participants were assessed for eligibility; a physical exam and 12-lead electrocardiogram were performed; vital signs were recorded and clinical laboratory samples were taken. Participants returned on day 0, when eligibility and vital signs were reviewed again and those who continued to meet eligibility criteria remained at the study site to enter the treatment phase.

Study endpoints

The primary pharmacodynamic endpoint was the percentage of time over 24 h on day 9 of each treatment phase that intragastric pH was >4.0 . The percentage of time over 24 h on day 1 that intragastric pH was >4.0 was assessed as a secondary endpoint. The percentage of time that intragastric pH was >3.0 and >5.0 on days 1 and 9 was also assessed.

Intragastric pH was measured by a pH probe (Digitrapper pH data logger; Medtronic, Minneapolis, MN, USA) placed prior to administration of study medication on day 1, with the distal electrode 10 cm below the lower oesophageal sphincter and the proximal electrode 5 cm above. The pH probe was removed in the morning of day 2 prior to morning (AM) dosing. This was repeated on day 9, with the probe removed on day 10. Collected pH data were evaluated by a third party blinded to study treatment.

On days 1 and 9 of each treatment period, pre-AM dose and serial post-AM dose blood samples were collected for pharmacokinetic (PK) assessments. Final blood samples were collected predose in the morning of day 2 and following completion of treatment on day 10.

The following PK parameters for esomeprazole and naproxen were calculated for each treatment after the AM and afternoon (PM) doses: peak plasma concentration ($C_{\max,AM}$ and $C_{\max,PM}$), time to peak plasma concentration ($t_{\max,AM}$ and $t_{\max,PM}$), area under the plasma concentration vs. time curve from time zero to the last time point with measurable drug concentration ($AUC_{0-t,AM}$ and $AUC_{0-t,PM}$) and half-life ($t_{1/2}$). AUC from time zero (time of dosing) to 10 h post-AM dose ($AUC_{0-10,AM}$), AUC from time zero to 14 h post-PM dose ($AUC_{0-14,PM}$) and a total daily AUC (AUC_{0-24}) were also calculated.

Safety for each treatment was assessed by the incidence of adverse events, a physical examination, vital signs and the following clinical laboratory tests: creatinine, alanine aminotransferase, aspartate aminotransferase, haematocrit, alkaline phosphatase, bilirubin, blood urea nitrogen, complete blood count and complete urinalysis.

Adverse events were recorded from the start of treatment until the final visit and were assessed for severity and relationship to study drug. Clinical laboratory tests, physical examination and measurement of vital signs were performed at screening and the final visit (on completion of the fourth treatment period or discontinuation). Vital signs were also measured in the PM of all days 0 and 8 visits, and complete blood count (without differential) was repeated on day 8 of the first three treatment periods and day 0 of the fourth period.

Statistical analysis

This study planned to enrol 28 subjects with the goal of having 24 evaluable subjects for analysis. A total of 24 subjects provided 80% power to reject the null hypothesis that the difference between each of the PN 400 treatments and the active control treatment in percentage of time that pH was >4.0 over 24 h was $\leq -8\%$ using a pairwise *t*-test with a one-sided significance level of 0.05.

All statistical analyses were completed using the SAS system, version 8.2 or higher (SAS Institute Inc., Cary, NC, USA). The intent-to-treat (ITT) population was defined as all randomized participants who had valid pH data for at least one treatment period (received all doses of study medication during that treatment period, had at least 20 h of valid pH data determined by the clinical investigator, did not have technical failures of the pH

recording and did not have ≥ 1 continuous hour with pH data outside the reference range). Primary pharmacodynamic analyses were based on the per protocol population (participants in the ITT population who had valid pH data for all four treatment periods and did not violate the protocol in any major way that would have impacted the evaluation of pharmacodynamic endpoints). The percentage of time that pH was >4.0 on days 1 and 9 was summarized by treatment and analysed by analysis of variance. The least squares (LS) means for each treatment, the difference of LS means between each of the PN 400 treatments and the active control and 95% confidence intervals (CIs) for all treatment differences were calculated.

Pharmacokinetic analyses were performed on the PK population (all randomized participants who received all doses of study medication for at least one treatment period and had adequate blood sampling to determine the PK parameters of the study drugs).

Plasma esomeprazole and naproxen concentration data were summarized by treatment and study day at each sampling time using descriptive statistics including mean, standard deviation, % coefficient of variance, median, minimum and maximum. Geometric mean and associated 95% CIs were also calculated for all PK parameters, except t_{\max} . Plasma concentrations below the lower limit of quantification were treated as a zero value for calculating descriptive statistics. The mean/median value at a time point with ≥ 1 value below the lower limit of quantification was reported unless the mean/median value was below the lower limit of quantification of the assay, in which case, the value was reported as below the lower limit of quantification.

The plasma concentration vs. time data of each analyte were subjected to noncompartmental analysis using WinNonlin version 4.1 (Pharsight Corporation, Mountain View, CA, USA). Statistical analysis was performed using analysis of variance to determine the point estimate and associated 90% CI of the days 9 to 1 ratios for the following parameters: $C_{\max,AM}$, $C_{\max,PM}$, $AUC_{0-10,AM}$, $AUC_{0-14,PM}$ and AUC_{0-24} . Natural log-transformed C_{\max} and AUC values were used for the analyses, thus geometric LS mean ratios for each parameter were determined.

Safety analyses were based on the safety population (all subjects who received at least one dose of study medication). Adverse events were coded by system organ class and preferred term according to the Medical Dictionary for Regulatory Activities (MedDRA, version 8.0). Vital signs and clinical laboratory test results were summarized by visit.

RESULTS

Participants

Twenty-eight participants were randomized to treatment and 27 completed the study (Figure 1). A majority of participants were male (68%) and all were white. Mean age was 24.9 years. Demographics and baseline characteristics of enrolled participants are shown in Table 2.

Pharmacodynamics

On day 9, the mean percentage of time where intragastric pH was >4.0 over 24 h was 76.5%, 71.4%, 40.9% and 59.9% for PN 400/E30, PN 400/E20, PN 400/E10 and naproxen + EC E20 respectively (Table 3). Compared with naproxen + EC E20 treatment, this percentage was significantly greater for PN 400/E30 and PN 400/E20 (95% CI: 13.0–26.0 and 7.8–20.7 respectively), but was significantly less for treatment with PN 400/E10 (95% CI: –22.3 to 9.7). Treatment with PN 400/E10 also resulted in the greatest variability of all treatments, as indicated by the high co-efficient of variation (Table 3).

Compared with observations on day 9, the mean percentage of time with intragastric pH >4.0 over 24 h was lower on day 1 for all treatment groups (27.8%, 20.5%, 12.8% and 21.3% for PN 400/E30, PN 400/E20,




Figure 1 | Subject disposition. ^aPremature withdrawal for personal reasons; ^bOn day 9 of period 4 (PN 400/E20) prior to completion of pH monitoring; ^cOn day 9 of period 3 (naproxen + EC E20). ITT, intent-to-treat; PK, pharmacokinetic; PP, per protocol.

Table 2 Baseline demographics (ITT population)	
	Total participants (n = 28)
Age (years)	
Mean (s.d.)	24.9 (3.9)
Median	24
Range	18–34
Gender, n (%)	
Male	19 (68)
Female	9 (32)
Race, n (%)	
White	28 (100)
Height (inches)	
Mean (s.d.)	70.1 (4.1)
Median	70.0
Range	63–79
Weight (lb)	
Mean (s.d.)	177.9 (34.6)
Median	178.0
Range	112–250
ITT, intent-to-treat; s.d., standard deviation.	

PN 400/E10 and naproxen + EC E20 respectively) (Table 3), although a similar pattern was observed with PN 400/E30 treatment, resulting in a greater percentage of time with intragastric pH >4.0 over 24 h compared with naproxen + EC E20 treatment (95% CI: 0.0–12.7).

As expected, compared with values reported for the percentage of time with intragastric pH >4.0 over 24 h, these percentages were higher for pH >3.0 and lower for pH >5.0 for all treatment groups on days 1 and 9 (data not shown). However, a similar treatment pattern was observed, with greater percentages reported for the PN 400/E30 and PN 400/E20 treatment groups compared with the naproxen + EC E20 treatment group.

On day 1, mean intragastric pH was low, ranging between pH 1.0 and 2.0, following an overnight fast and prior to any treatment (Figure 2b). By day 9, the range following overnight fast had increased to pH 2.0–3.0 for all treatments (Figure 2a).

Three pH surges were observed over 24 h on days 1 and 9, occurring approximately 1 h after food intake for all treatments at 1, 6 and 11 h (Figure 2). On day 9, esomeprazole in all treatments was observed to have a dose-related effect on gastric pH beyond the influence of

Table 3 Percentage of time with gastric pH >4.0 over 24 h on days 9 and 1 (PP population)	Day 1					
	Day 9		Day 1		Day 1	
Time pH >4.0 (%)	PN 400/E30, n = 25	PN 400/E20, n = 25	PN 400/E10, n = 25	Naproxen + EC E20, n = 25	PN 400/E30, n = 25	PN 400/E20, n = 25
Mean (s.d.)	76.5 (12.3)	71.4 (13.0)	40.9 (22.5)	56.9 (10.1)	27.8 (22.6)	20.5 (16.6)
Median	78.8	70.4	35.8	55.1	20.0	15.3
% coefficient of variation	16	18	55	18	81	81
Range	49.8–95.3	51.8–97.6	10.3–85.3	40.6–75.5	1.8–89.6	4.4–74.4
LS mean (S.E.)	76.8 (3.0)	71.5 (3.0)	41.1 (3.0)	57.2 (3.0)	27.9 (3.3)	20.6 (3.3)
LS mean difference vs. naproxen + EC E20 (S.E.)	19.5 (3.3)	14.2 (3.3)	–16.1 (3.3)	–	6.4 (3.2)	–0.92 (3.2)
95% CI	13.0–26.0	7.8–20.7	–(22.3–9.7)	–	0.0–12.8	–(7.3–5.4)
PP, per protocol; EC, enteric coated; s.d., standard deviation; LS, least-squares; S.E., standard error; CI, confidence interval.						




Figure 2 | (a) Mean intragastric pH over 24 h on day 9; (b) mean intragastric pH over 24 h on day 1 (PP population). PP, per protocol; EC, enteric coated.

food intake. Following administration of the morning dose of PN 400 formulations, rapid, dose-related increases in pH were observed approximately 1 h earlier than food-induced increases in pH (Figure 2a). In contrast, there was a comparative delay in pH increase related to morning administration of EC E20 with naproxen + EC E20 treatment.

After 9 days of treatment, PN 400/E30 and PN 400/E20 had a similar effect on gastric pH with an observed slower return to low pH levels after food intake compared with PN 400/E10 and naproxen + EC E20. In contrast, on day 1, doses of esomeprazole in any treatment had a minimal effect on gastric pH beyond the effect of food intake (Figure 2b).

Pharmacokinetics

The PK parameters of esomeprazole and naproxen for all treatments following administration of the AM and PM

doses on days 1 and 9 are summarized in Table 4. The steady-state EC naproxen plasma profiles were comparable among the three PN 400 treatments.

Following AM or PM doses on days 1 and 9, plasma IR esomeprazole concentrations increased with the esomeprazole dose across the three PN 400 treatments. On both days, the measurable plasma concentrations of IR esomeprazole were higher following the AM dose than the PM dose for all three PN 400 treatments (Figure 3a-b).

On day 1, quantifiable plasma concentrations of IR esomeprazole were obtained rapidly with all three PN 400 treatments at 10 min after the AM dose, and at 20–30 min after administration of the PM dose (Figure 3a). IR esomeprazole was rapidly eliminated from plasma in the majority of subjects by 6–8 h postdose (AM and PM) for all three PN 400 treatments (Figure 3a).

On day 9, pre-AM dose blood samples showed that esomeprazole concentrations were quantifiable in 19 subjects receiving PN 400/E30 treatment, 13 receiving PN 400/E20 treatment and six receiving PN 400/E10 treatment. Post-AM and PM dose samples showed that in the PN 400 treatments containing higher IR esomeprazole doses (PN 400/E30 and PN 400/E20), plasma concentrations of esomeprazole were quantifiable at earlier postdose time points in a large number of subjects and for a longer period compared with day 1 (Figure 3b).

Following administration of naproxen + EC E20 treatment on days 1 and 9, measurable plasma concentrations of EC esomeprazole were not available until 0.75–1.5 h postdose in the majority of subjects and were measurable for longer than concentrations following PN 400 administration (Figure 3a,b).

The mean plasma profiles of EC naproxen were comparable following the three PN 400 treatments, particularly on day 9 (Figure 3c,d), demonstrating delayed-release characteristics consistent with the EC formulation in PN 400, with higher mean plasma naproxen concentration levels observed at the end of a 24-h interval.

On day 1, quantifiable plasma concentrations of EC naproxen were first detected at approximately 2 h post-PN 400 administration for all three PN 400 treatments (Figure 3c). By day 9, pre-AM dose samples showed that EC naproxen concentrations were quantifiable in all participants throughout the entire sampling time (Figure 3d), and mean plasma concentrations were much higher than observed on day 1.

Following non-EC naproxen treatment on days 1 and 9, plasma naproxen concentrations were measurable in all subjects at the 10-min postdose sample time and for

Table 4 Summary of esomeprazole and naproxen pharmacokinetic parameters on days 1 and 9 (PK population)						
Treatment, day and dose	Esomeprazole			Naproxen		
	C_{\max} (ng/mL)	t_{\max} (h)	AUC* (h·ng/mL)	C_{\max} (ng/mL)	t_{\max} (h)	AUC* (h·ng/mL)
PN 400/E30 ($n = 28$)						
Day 1, AM	487 (82)	0.50 (0.33-1.50)	591 (108)	48.1 (53)	4.00 (2.00-10.00)	259 (56)
Day 1, PM	187 (132)	1.50 (0.33-4.00)	388 (137)	68.9 (28)	14.00 (0.50-14.00)	471 (30)
PN 400/E20 ($n = 28$)						
Day 1, AM	292 (77)	0.50 (0.20-1.50)	350 (113)	44.4 (68)	4.00 (2.00-10.00)	231 (70)
Day 1, PM	96.6 (104)	1.49 (0.33-3.00)	206 (141)	71.5 (26)	14.00 (0.00-14.00)	450 (33)
PN 400/E10 ($n = 27$)						
Day 1, AM	138 (71)	0.33 (0.17-3.10)	148 (111)	57.0 (31)	4.00 (2.00-10.00)	310 (35)
Day 1, PM	35.3 (84)	1.50 (0.33-3.00)	85.7† (179)	68.6 (26)	10.00 (0.00-14.00)	508 (29)
Naproxen + EC E20 ($n = 28$)						
Day 1, AM	282 (66)	1.50 (1.00-16.00)	540† (60)	65.5 (25)	1.50 (0.75-6.00)	409 (16)
Day 1, PM				81.5 (14)	1.50 (0.50-2.50)	685 (10)
PN 400/E30 ($n = 28$)						
Day 9, AM	1584 (39)	0.50 (0.17-1.50)	2779 (45)	80.9 (23)	3.00 (0.00-8.00)	603 (21)
Day 9, PM	810 (59)	1.00 (0.33-8.00)	2066 (53)	76.2 (23)	10.40 (0.00-14.00)	648 (20)
PN 400/E20 ($n = 27$)						
Day 9, AM	715 (52)	0.50 (0.17-1.50)	1216 (69)	86.2 (22)	3.00 (0.00-8.05)	607 (19)
Day 9, PM	428 (73)	0.75 (0.33-3.00)	919 (84)	76.8 (18)	10.00 (0.00-14.00)	678 (16)
PN 400/E10 ($n = 27$)						
Day 9, AM	278 (57)	0.33 (0.17-1.00)	368 (89)	87.1 (21)	2.50 (0.00-8.00)	637 (17)
Day 9, PM	97.6 (136)	1.00 (0.33-2.00)	223† (134)	78.6 (17)	14.00 (1.50-14.00)	672 (19)
Naproxen + EC E20 ($n = 28$)						
Day 9, AM	435 (48)	1.50 (1.00-14.00)	1046 (54)	90.0 (19)	1.50 (0.50-4.00)	617 (12)
Day 9, PM	-	-	-	86.5 (13)	1.50 (0.75-4.00)	769 (10)

Values are mean (% coefficient of variation) for C_{\max} and AUC, and median (range) for t_{\max} .

PK, pharmacokinetic; C_{\max} , peak plasma concentration; t_{\max} , time to peak plasma concentration; AUC, area under the plasma concentration vs. time curve.

*AUC_{0-10,AM} or AUC_{0-14,PM}.

† $n = 26$.

up to 24 h, consistent with a non-EC naproxen formulation (Figure 3c,d).

Safety

In general, study treatments were well tolerated. The overall incidence of adverse events ranged from 29% with naproxen + EC E20 to 50% with PN 400/E30 and PN 400/E20. A majority were mild and no participants reported serious adverse events or withdrew from the study due to adverse events.

The most common adverse events (reported by $\geq 10\%$ of participants during any treatment) were diarrhoea, upper abdominal pain, iron deficiency and headache (Table 5). Gastrointestinal adverse events were reported in 29–32% of subjects receiving PN 400 treatments and 18% of subjects receiving naproxen + EC E20 (Table 5). The incidence of treatment-related adverse events was 39% ($n = 11$), 29% ($n = 8$), 26% ($n = 7$) and 21% ($n = 6$) during treatment with PN 400/E30, PN 400/E20, PN 400/E10 and naproxen + EC E20 respectively. The




Figure 3 | (a) Mean plasma esomeprazole concentration vs. time on day 1; (b) mean plasma esomeprazole concentration vs. time on day 9; (c) mean plasma naproxen concentration vs. time on day 1; (d) mean plasma naproxen concentration vs. time on day 9 (PK population). PK, pharmacokinetic; EC, enteric coated.

most frequent treatment-related adverse events reported by $\geq 10\%$ of participants during any treatment were gastrointestinal and nervous system disorders, including diarrhoea ($n = 2-4$), upper abdominal pain ($n = 0-3$) and headache ($n = 0-3$).

Decreases in haematocrit, haemoglobin and/or red blood cell counts throughout the study were observed in all 28 participants. However, most cases were small deviations from the normal range and were not considered by the investigator to be related to study treatment, but as a result of blood sampling throughout the study. Vital sign measurements and physical examinations were similar at screening and the final visit.

DISCUSSION

This study showed that IR esomeprazole 20 mg or 30 mg in PN 400 b.d. provided gastric acid suppression comparable to EC esomeprazole 20 mg o.d. The study also demonstrated that PN 400 provided early onset of increased intragastric pH at steady state before EC naproxen was released. In addition, following administration of the PN 400 formulations, IR esomeprazole was rapidly absorbed with relatively high plasma concentrations measurable at an earlier time postdose compared with EC esomeprazole. Thus, the PK parameters and plasma profiles of esomeprazole and naproxen, together with the intragastric pH profiles obtained on day 9, were consistent with the sequential-release design of PN 400 to achieve rapidly a gastroprotective environment.

It is understood that NSAID-associated gastroduodenal damage can be substantially reduced by elevating the luminal pH above 4.0.¹⁷ Our results are comparable to previous studies that reported that, after 5 days of o.d. dosing, the percentage of time that gastric pH was >4.0 was approximately 50% for EC E20 and 70% for EC E40.^{15, 18} Both of these dosages have also been approved for the risk reduction of NSAID-associated gastric ulcer.¹⁶ In this study, PN 400 containing 20 or 30 mg of IR esomeprazole resulted in greater time with pH >4.0 over 24 h on day 9 than the control treatment of naproxen 500 mg b.d. and EC esomeprazole 20 mg o.d. given separately.

Based on these results, where PN 400/E10 provided highly variable and insufficient pH control, and PN 400/E30 was not significantly better than PN 400/E20 in providing additional pH control, PN 400/E20 was selected for further studies to evaluate the gastrointestinal and analgesic efficacy of PN 400. Indeed, in a recent Phase 3 study, PN400/E20 demonstrated a significant reduction

Table 5 | Clinical adverse events (Safety population), *n* (%)

	PN 400/E30 (<i>n</i> = 28)	PN 400/E20 (<i>n</i> = 28)	PN 400/E10 (<i>n</i> = 27)	Naproxen + EC E20 (<i>n</i> = 28)
Participants with ≥1 adverse event	14 (50.0)	14 (50.0)	9 (33.3)	8 (28.6)
Gastrointestinal disorders	9 (32.1)	8 (28.6)	8 (29.6)	5 (17.9)
Diarrhoea	4 (14.3)	4 (14.3)	3 (11.1)	2 (7.1)
Abdominal distension	2 (7.1)	2 (7.1)	2 (7.4)	2 (7.1)
Dyspepsia	1 (3.6)	2 (7.1)	1 (3.7)	1 (3.6)
Abdominal pain (upper)	3 (10.7)	0 (0.0)	1 (4.0)	0 (0.0)
Constipation	1 (3.6)	1 (3.6)	1 (3.7)	0 (0.0)
Epigastric discomfort	1 (3.6)	0 (0.0)	1 (3.7)	0 (0.0)
Gastroenteritis (viral)	0 (0.0)	0 (0.0)	2 (7.4)	0 (0.0)
Abdominal pain (lower)	0 (0.0)	1 (3.6)	0 (0.0)	0 (0.0)
Metabolism and nutrition disorders	3 (10.7)	5 (17.9)	1 (3.7)	1 (3.6)
Iron deficiency	3 (10.7)	5 (17.9)	1 (3.7)	1 (3.6)
General disorders	1 (3.6)	2 (7.1)	1 (3.7)	1 (3.6)
Fatigue	1 (3.6)	1 (3.6)	1 (3.7)	1 (3.6)
Influenza-like illness	0 (0.0)	1 (3.6)	0 (0.0)	0 (0.0)
Nervous system disorders	4 (14.3)	1 (3.6)	0 (0.0)	0 (0.0)
Headache	3 (10.7)	1 (3.6)	0 (0.0)	0 (0.0)
Dizziness	1 (3.6)	0 (0.0)	0 (0.0)	0 (0.0)

EC, enteric coated.

in the incidence of endoscopic gastric ulcers and improved upper gastrointestinal tolerability compared with EC naproxen 500 mg alone in at-risk patients with arthritis.^{19, 20}

A site error resulted in the use of a non-EC formulation of naproxen in the control treatment. This error was identified after study completion following the discovery of atypical PK results. However, as the plasma concentrations of IR esomeprazole were measurable earlier than non-EC naproxen on day 9, this error does not affect the study interpretation.

Perhaps surprisingly, the absorption of IR esomeprazole following the PM dose of PN 400 was delayed compared with AM dosing, and plasma esomeprazole concentrations after the PM dose were lower than after the AM dose. This may be explained by slower gastric emptying time following lunch and dinner on the day of dosing. Increased gastric residence time may also have resulted in some degradation of esomeprazole from PN 400 and the prolonged t_{\max} observed after the PM dose on days 1 and 9. The increase in plasma

esomeprazole concentrations with repeated doses of PN 400 may be attributed to reduced degradation along with decreased systemic drug metabolism via inhibition of cytochrome P450 2C19 by esomeprazole.²¹

This study was also able to demonstrate a lack of PK drug–drug interactions between EC naproxen and IR esomeprazole when co-administered as a fixed-dose combination. This can be interpreted from the finding that the dose level of IR esomeprazole in PN 400 did not affect the steady-state plasma exposure to naproxen.

In the present study, PN 400 containing 30, 20 or 10 mg of IR esomeprazole was well tolerated in 9-day b.d. treatment periods in healthy subjects. The incidence of all adverse events experienced with PN 400 was somewhat higher than with naproxen + EC E20, including the incidence of gastrointestinal events (diarrhoea, upper abdominal pain). The apparent increase in treatment-related adverse events observed with increasing dose of IR esomeprazole in the three different PN 400 formulations suggests that some of these adverse events may be related to esomeprazole rather than to EC naproxen.

However, these findings must be interpreted with caution given the low number of events reported for each treatment as well as the erroneous use of non-EC naproxen in the control treatment that prevents direct comparison. Furthermore, reported adverse events were mild, and none led to discontinuation from the study. Abnormal decreases in haematology assessments throughout the study were not considered related to study treatment, but as a result of repeated blood sampling.

CONCLUSIONS

PN 400/E20 was the lowest PN 400 IR esomeprazole dose to achieve a level of acid suppression comparable to EC esomeprazole 20 mg with appropriate consistency of effect.

The pharmacodynamic and PK profiles of esomeprazole and naproxen in PN 400 demonstrate that IR esomeprazole can be effectively combined with EC naproxen, producing an early onset of increased gastric pH before naproxen is released.

Based on these results, PN 400/E20 has been selected for future studies evaluating the PN 400 formulation.

ACKNOWLEDGEMENTS

Declaration of personal interests: Philip Miner receives research support from Abbott, Allergan, ARYx, AstraZeneca, Axcan, Biogen, Centocor, Eisai, Forest, Lexicon, Otsuka, Procter and Gamble, Prometheus, PLX, POZEN, Salix, Schering Plough, Takeda, UCB, Vecta and Ventrus. He is a consultant to Abbott, Allergan, ARYx, AstraZeneca, Atlantic, Axcan, Biogen, Centocor, Movetis, POZEN, Salix, Sanofi-Aventis, Schering Plough, Takeda, UCB, Vecta, Ventrus and Wyeth. Dr Miner has participated in speakers' bureaux for AstraZeneca and Axcan, and has participated in scientific advisory boards for ARYx, AstraZeneca, Atlantic, Axcan, Biogen, Forest, Procter and Gamble, Salix, UCB and Ventrus. He has patent interests in ISIS. John Plachetka, Eric Orlemans and John Fort are employees of POZEN, Inc. with stock options. Mark Sostek is an employee of AstraZeneca. *Declaration of funding interests:* This study was funded in full by POZEN Inc. Writing support was provided by Lynsey Stevenson of Complete Medical Communications, and was funded by AstraZeneca.

REFERENCES

- Singh G. Gastrointestinal complications of prescription and over-the-counter nonsteroidal anti-inflammatory drugs: a view from the ARAMIS database. Arthritis, Rheumatism, and Aging Medical Information System. *Am J Ther* 2000; **7**: 115–21.
- Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. *Gastroenterology* 2001; **120**: 594–606.
- Laine L, Bombardier C, Hawkey CJ, *et al.* Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. *Gastroenterology* 2002; **123**: 1006–12.
- Lanza FL, Chan FK, Quigley EMM. Guidelines for prevention of NSAID-related ulcer complications. *Am J Gastroenterol* 2009; **104**: 728–38.
- Hawkey CJ, Karrasch JA, Szczepanski L, *et al.* Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. *N Engl J Med* 1998; **338**: 727–34.
- Scheiman JM. Prevention of NSAID-induced ulcers. *Curr Treat Options Gastroenterol* 2008; **11**: 125–34.
- Sturkenboom MC, Burke TA, Dieleman JP, *et al.* Underutilization of preventive strategies in patients receiving NSAIDs. *Rheumatology (Oxford)* 2003; **42**(Suppl. 3): 23–31.
- Abraham NS, El-Serag HB, Johnson ML, *et al.* National adherence to evidence-based guidelines for the prescription of nonsteroidal anti-inflammatory drugs. *Gastroenterology* 2005; **129**: 1171–8.
- Sturkenboom MCJM, Burke TA, Tangelder MJD, *et al.* Adherence to proton pump inhibitors or H₂-receptor antagonists during the use of non-steroidal anti-inflammatory drugs. *Aliment Pharmacol Ther* 2003; **18**: 1137–47.
- van Soest EM, Sturkenboom MCJM, Dieleman JP, *et al.* Adherence to gastroprotection and the risk of NSAID-related upper gastrointestinal ulcers and haemorrhage. *Aliment Pharmacol Ther* 2007; **26**: 265–75.
- Goldstein JL, Howard KB, Walton SM, *et al.* Impact of adherence to concomitant gastroprotective therapy on nonsteroidal-related gastroduodenal ulcer complications. *Clin Gastroenterol Hepatol* 2006; **4**: 1337–45.
- Kearney PM, Baigent C, Godwin J, *et al.* Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. *BMJ* 2006; **332**: 1302–8.
- McGettigan P, Henry D. Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. *JAMA* 2006; **296**: 1633–44.
- Singh G, Fort JG, Goldstein JL, *et al.* Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study. *Am J Med* 2006; **119**: 255–66.
- Miner P Jr, Katz PO, Chen Y, *et al.* Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. *Am J Gastroenterol* 2003; **98**: 2616–20.
- Scheiman JM, Yeomans ND, Talley NJ, *et al.* Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAIDs and COX-2 inhibitors. *Am J Gastroenterol* 2006; **101**: 701–10.
- Yeomans ND. New data on healing of nonsteroidal anti-inflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee. *Am J Med* 1998; **104**: 56S–61S.

18. Wilder-Smith C, Lind T, Lundin C, *et al.* Acid control with esomeprazole and lansoprazole: a comparative dose-response study. *Scand J Gastroenterol* 2007; **42**: 157–64.
19. Goldstein JL, Sostek MB, Fort JG, *et al.* A single-tablet multilayer formulation of enteric-coated naproxen coupled with non-enteric-coated omeprazole is associated with a significantly reduced incidence of gastric ulcers vs. enteric-coated naproxen: a prospective, randomized, double-blind study. *Gastroenterology* 2008; **134**(Suppl 1): A-19.
20. Goldstein JL, Hochberg M, Fort JG, *et al.* PN400 significantly improved upper gastrointestinal tolerability compared with enteric-coated naproxen alone in patients requiring chronic NSAID therapy: results from two prospective, randomized controlled trials. *Am J Gastroenterol* 2009; **104**: S50.
21. Hassan-Alin M, Andersson T, Bredberg E, *et al.* Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects. *Eur J Clin Pharmacol* 2000; **56**: 665–70.